The effectiveness and sustainability of health outcomes from an advanced GLP-1-supported digital weight-loss programme in the UK: a randomized controlled trial

Eucalyptus0 个研究点目标入组 1,000 人开始时间: 2024年5月27日最近更新: 2024年6月10日

试验速览

暂无简介。

•1. Between 18 years and 70 years of age at the time of completing the program’s pre-questionnaire
•2. Satisfy the Medicines and Healthcare products Regulatory Agency (MHRA) guidelines for tirzepatide (Mounjaro) weight management
•3. BMI of 30kg/m² or more (obesity), or a BMI between 27-30kg/m² (overweight) and also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems

•1. Outside the 18-70 year age bracket
•2. Does not have a BMI of 30 kg/m2 or more, or a BMI of 27-30 kg/m2 with at least one weight-related comorbidity such as pre-diabetes, high blood pressure, high cholesterol, heart problems
•3. Has already started tirzepatide treatment as a current subscriber to the Eucalyptus weight-loss program
•4. Failure to provide baseline measurements within three weeks of receiving confirmation of trial participation

发起方

Eucalyptus